Related Experiment Video

Updated: May 15, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Targeting triple negative breast cancer: is p53 the answer?

Natalie Turner1, Erica Moretti, Olimpia Siclari

  • 1Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy.

Cancer Treatment Reviews
|January 17, 2013
PubMed

Insights

Triple negative breast cancer (TNBC) is aggressive and lacks effective therapies. This review explores novel treatments targeting p53 mutations, offering hope for this challenging breast cancer subtype.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple negative breast cancer (TNBC) accounts for 15% of breast cancers but a higher proportion of mortality.
  • TNBC is characterized by the absence of estrogen, progesterone, and HER2 receptors, leading to aggressive biology and limited treatment options.
  • Current treatments like conventional chemotherapy are insufficient, and emerging therapies like PARP and EGFR inhibitors show limited efficacy in sporadic TNBC.

Purpose of the Study:

  • To review novel therapeutic agents targeting aberrant p53 signaling in triple negative breast cancer.
  • To identify potential targeted therapies for TNBC by focusing on p53 mutations, which are prevalent in this subtype.

Main Methods:

  • Literature review of emerging therapeutic agents.
  • Analysis of agents with potential activity against aberrant p53 signaling.
  • Focus on novel approaches for TNBC treatment.

Main Results:

  • p53 mutations are found in the majority of triple negative breast cancers, making it a key target.
  • Several agents show potential activity against aberrant p53 signaling.
  • Emerging therapeutic strategies are being explored beyond conventional chemotherapy.

Conclusions:

  • Targeting p53 signaling represents a promising novel approach for treating triple negative breast cancer.
  • There is a critical need for effective targeted therapies for TNBC due to its aggressive nature and poor outcomes.
  • Further investigation into agents targeting p53 is warranted for developing effective treatments for this aggressive breast cancer subtype.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...